J&J defends itself in trial over baby powder asbestos claims
(Reuters) – A trial for a lawsuit alleging that Johnson & Johnson Baby Powder was responsible for the death of a woman due to her exposure to cancer-causing asbestos began…
FDA says Mylan’s EpiPen is in shortage
(Reuters) – U.S. regulators said on Wednesday that Mylan NV’s (MYL.O) EpiPen products are in shortage, due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy…
FDA chief questions protections on drug rebates, stocks fall
(Reuters) – U.S. Food and Drug Administration chief Scott Gottlieb on Thursday questioned whether rebates that drugmakers provide to health insurers should remain protected by federal law, sparking new concerns…
Breast cancer screening failure may have shortened 270 lives in England
LONDON (Reuters) – As many as 270 women’s lives may have been shortened after an IT failure in England’s breast cancer screening program meant 450,000 patients were not invited for…
Allergan migraine drug succeeds in second late-stage trial
NEW YORK (Reuters) – Allergan Plc on Friday announced positive results from a second Phase III trial for the 50 milligram dose of its drug for acute migraine, reproducing results…
Ninety-eight now sick from romaine lettuce-linked E. coli: CDC
(Reuters) – Fourteen more people fell ill from an E. coli outbreak linked to romaine lettuce, U.S. health officials said on Friday, bringing the number of people affected to 98…
Fourteen more fall sick from E. coli linked to romaine lettuce: CDC
(Reuters) – Fourteen more sick people from eight U.S. states were added to an investigation of an E. coli outbreak linked to romaine lettuce, the U.S. Centers for Disease Control…
FDA cracks down on sales of Juul tobacco products to minors
(Reuters) – The U.S. Food and Drug Administration on Tuesday said it launched a crackdown on the sale of e-cigarettes and tobacco products to minors, particularly those developed by Juul…
Jilted Akorn sues Fresenius over deal termination
FRANKFURT (Reuters) – U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement. FILE PHOTO: Fresenius headquarters in…
FDA declines to approve Pfizer’s biosimilar to Roche’s cancer drug
(Reuters) – Pfizer Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve the company’s biosimilar to Roche’s breast cancer drug, Herceptin, and sought additional technical…